Learn more about Apellis-sponsored ongoing clinical trials below.
DiseaseAutoimmune Hemolytic Anemia (AIHA)
StudyPLAUDIT Clinical Trial: A phase 2, prospective, open-label study to assess the safety, tolerability, preliminary efficacy, pharmacokinetics and pharmacodynamics of multiple doses of APL-2 in patients with autoimmune hemolytic anemia (AIHA).
This phase 2 clinical study of APL-2 for the treatment of AIHA is enrolling 12 patients across two cohorts; six patients in the in warm autoimmune hemolytic anemia (wAIHA) arm and six patients in the cold agglutinin disease (CAD) arm. For qualified patients who do not live near the study locations, Apellis will reimburse for costs associated with travel, if needed.